Adjuvant formulations for virus-like particle (VLP) based vaccines.
Adjuvant formulations for virus-like particle (VLP) based vaccines.
复制标题
DOI:
10.1016/j.clim.2017.08.004
复制
发表时间:
2017-10
期刊:
影响因子:
--
通讯作者:
Galarza JM
中科院分区:
文献类型:
--
作者:
Cimica V;Galarza JM
The development of virus-like particle (VLP) technology has had an enormous impact on modern vaccinology. In order to optimize the efficacy and safety of VLP-based vaccines, adjuvants are included in most vaccine formulations. To date, most licensed VLP-based vaccines utilize the classic aluminum adjuvant compositions. Certain challenging pathogens and weak immune responder subjects may require further optimization of the adjuvant formulation to maximize the magnitude and duration of the protective immunity. Indeed, novel classes of adjuvants such as liposomes, agonists of pathogen recognition receptors, polymeric particles, emulsions, cytokines and bacterial toxins, can be used to optimize the immunostimulatory activity of a VLP-based vaccine. This review describes the current advances in adjuvant technology for VLP-based vaccines directed at viral diseases, and discusses the basic principles for designing adjuvant formulations for enhancing the vaccine immunogenicity. VLPs can be produced from various cellular systems using recombinant DNA technology. Adjuvants play multiple roles in enhancing the efficacy and safety of VLP-based vaccines.
登录
查看更多内容
影响因子:
6.2
作者:
Bode C;Zhao G;Steinhagen F;Kinjo T;Klinman DM
通讯作者:
Klinman DM
DOI:
10.1056/nejmoa1101245
发表时间:
2011-12-08
期刊:
The New England journal of medicine
影响因子:
--
作者:
Atmar RL;Bernstein DI;Harro CD;Al-Ibrahim MS;Chen WH;Ferreira J;Estes MK;Graham DY;Opekun AR;Richardson C;Mendelman PM
通讯作者:
Mendelman PM
影响因子:
3.7
作者:
Clegg CH;Roque R;Perrone LA;Rininger JA;Bowen R;Reed SG
通讯作者:
Reed SG
影响因子:
4.6
作者:
Beran, Jiri
通讯作者:
Beran, Jiri
影响因子:
4.9
作者:
Ambuehl, Patrice M.;Tissot, Alain C.;Bachmann, Martin F.
通讯作者:
Bachmann, Martin F.